Ajinomoto acquires Japanese risedronate rights
This article was originally published in Scrip
The diversified Japanese company Ajinomoto is paying $210 million to Procter & Gamble for the full rights in its home market to the osteoporosis drug risedronate, for which it is already the local licensee.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.